EFFECT OF GLUTATHIONE ON DNA-REPAIR IN CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES

被引：177
|
作者：
LAI, GM
OZOLS, RF
YOUNG, RC
HAMILTON, TC
机构：
[1] FOX CHASE CANC CTR, DEPT MED ONCOL, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA
[2] NCI, MED BRANCH, BETHESDA, MD 20205 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1989年 / 81卷 / 07期
关键词：
D O I：
10.1093/jnci/81.7.535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：535 / 539
页数：5
相关论文
共 50 条
  • [41] IN-VIVO SCREENING MODELS OF CISPLATIN-RESISTANT HUMAN LUNG-CANCER CELL-LINES USING SCID MICE
    HEIKE, Y
    TAKAHASHI, M
    OHIRA, T
    ARIOKA, H
    FUNAYAMA, Y
    NISHIO, K
    OGASAWARA, H
    SAIJO, N
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) : 200 - 204
  • [42] HUMAN-ANTIBODIES TO OVARIAN-CANCER ANTIGENS SECRETED BY LYMPHOBLASTOID CELL-LINES
    ALAZZAWI, F
    STIMSON, WH
    GOVAN, ADT
    [J]. JOURNAL OF CLINICAL & LABORATORY IMMUNOLOGY, 1987, 22 (02) : 71 - 75
  • [43] SELECTIVE POTENTIATION OF PLATINUM DRUG CYTOTOXICITY IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES BY AMPHOTERICIN-B
    SHARP, SY
    MISTRY, P
    VALENTI, MR
    BRYANT, AP
    KELLAND, LR
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 35 (02) : 137 - 143
  • [44] ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS
    PIETRAS, RJ
    FENDLY, BM
    CHAZIN, VR
    PEGRAM, MD
    HOWELL, SB
    SLAMON, DJ
    [J]. ONCOGENE, 1994, 9 (07) : 1829 - 1838
  • [45] PRECLINICAL ACTIVITY OF A NEW PLATINUM ANALOG, LOBAPLATIN, IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN TESTICULAR, OVARIAN, AND GASTRIC-CARCINOMA CELL-LINES
    HARSTRICK, A
    BOKEMEYER, C
    SCHARNOFKSE, M
    HAPKE, G
    REILE, D
    SCHMOLL, HJ
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (01) : 43 - 47
  • [46] IMMUNOLOGICAL CHARACTERIZATION OF TUMOR-MARKERS IN HUMAN OVARIAN-CANCER CELL-LINES
    MATHIS, JM
    KUTTEH, WH
    MILLER, DS
    [J]. JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A310 - A310
  • [47] Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol
    Perego, P
    Romanelli, S
    Carenini, N
    Magnani, I
    Leone, R
    Bonetti, A
    Paolicchi, A
    Zunino, F
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (04) : 423 - 430
  • [48] Effect of combined treatment of Eribulin with Cisplatin in Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines
    Seeber, M.
    Koester, F.
    Polack, S.
    Rody, A.
    Braeutigam, K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 180 - 180
  • [49] ADRIAMYCIN ACCUMULATION AND METABOLISM IN ADRIAMYCIN-SENSITIVE AND ADRIAMYCIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES
    LOUIE, KG
    HAMILTON, TC
    WINKER, MA
    BEHRENS, BC
    TSURUO, T
    KLECKER, RW
    MCKOY, WM
    GROTZINGER, KR
    MYERS, CE
    YOUNG, RC
    OZOLS, RF
    [J]. BIOCHEMICAL PHARMACOLOGY, 1986, 35 (03) : 467 - 472
  • [50] A ROLE OF GLUTATHIONE IN RESISTANCE MECHANISMS TO CIS-DIAMMINEDICHLOROPLATINUM(II) IN HUMAN OVARIAN-CANCER CELL-LINES IN-VITRO
    KUDOH, K
    KIKUCHI, Y
    HIRATA, J
    KITA, T
    HIRAMATSU, H
    TODE, T
    NAGATA, I
    [J]. ONCOLOGY REPORTS, 1995, 2 (05) : 763 - 768
12345